ad image
Sotera Health's Nordion completes the sale of its medical isotopes business to BWXT

Sotera Health's Nordion completes the sale of its medical isotopes business to BWXT

Aug 17, 2018PR-M08-18-NI-065-3828

Nordion's increased focus on gamma technologies supports Sotera Health's company-wide commitment to Safeguarding Global Health™

BROADVIEW HEIGHTS, Ohio/PRNewswire/ -- Sotera Health LLC, the world's leading, fully integrated protector of global health, today announced the closing of the sale of the Medical Isotopes segment within its Nordion business to BWX Technologies, Inc. (BWXT).

With the sale, BWXT now owns Nordion's former medical isotopes business, including the radiochemical and contract manufacturing operations in Kanata, Ontario, and the isotope production facility in Vancouver, British Columbia, along with transfer of approximately 150 employees. Nordion retains ownership of its gamma technologies business as well as its state-of-the-art licenced facility in Kanata. Separately, the companies also signed a long-term lease agreement that will allow BWXT to continue operating from Nordion's Kanata facility.

"We are seeing significant growth and new business opportunities for gamma technologies, especially in the exciting new therapeutic applications that are emerging for medical cobalt-60," said Michael Petras, Chief Executive Officer of Sotera Health. "This sale allows Nordion to focus its full attention on accelerating growth in gamma technologies to bring our customers additional value in support of our Sotera Health mission, Safeguarding Global Health™."